Showing results (761-770 of 933) with videos related to

Sort By:
Pageof 94
Oncogene|November 1, 1992
Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cellsR Halaban, J S Rubin, Y Funasaka, et al.
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rateM Markman, B Reichman, T Hakes, et al.
The Journal of Craniofacial Surgery|December 16, 2014
Endogenous cell therapy improves bone healingJohn Layliev, Alexander Marchac, Rica Tanaka, et al.
Journal of Human Hypertension|November 20, 2015
From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergencyA Cremer, F Amraoui, G Y H Lip, et al.
Gynecologic Oncology|May 1, 1993
The use of recombinant human erythropoietin to prevent carboplatin-induced anemiaM Markman, B Reichman, T Hakes, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|March 15, 2005
Infective endocarditis following orthotopic heart transplantation: 10 cases and a review of the literatureS Sherman-Weber, P Axelrod, B Suh, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1993
Intraperitoneal administration of Taxol in the management of ovarian cancerM Markman, E Rowinsky, T Hakes, et al.
Frontiers in Pharmacology|July 18, 2019
The Insula: A Brain Stimulation Target for the Treatment of AddictionChristine Ibrahim, Dafna S Rubin-Kahana, Abhiram Pushparaj, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.
Seminars in Oncology|December 11, 1992
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?M Markman, T Hakes, B Reichman, et al.
Pageof 94